鼻息肉患者血清抗EBV-LMP1抗体的检测及其临床意义

Detection and significance of anti-EBV-LMP1 antibody in patients with nasal polyps

目的:检测鼻息肉患者血清抗Epstain-Barr病毒(EBV)潜伏膜蛋白1(LMP1)抗体并探讨其临床意义。方法:行功能性鼻内镜手术治疗的鼻息肉患者20例为实验组,健康自愿者20例为对照组。以谷胱甘肽-EBV-LMP1胞外区融合蛋白(GST-LMP1)为检测抗原,ELISA和Western blot检测健康自愿者和鼻息肉患者手术治疗前、治疗后第15、30、90、180天血清抗EBV-LMP1抗体。结果:ELISA检测鼻息肉患者和健康自愿者血清抗EBV-LMP1抗体水平分别为0.976±0.131、0.400±0.102,两组比较有统计学差异(P<0.01)。鼻息肉患者术前和术后第15、30、90、180天血清抗EBV-LMP1抗体水平分别为:0.976±0.131、0.921±0.138、0.899±0.168、0.576±0.144、0.521±0.117,术后第90、180天与术前比较,差异有统计学意义(P<0.01);但是术后第15、30天与术前比较,无统计学差异。Western blot检测鼻息肉患者术前血清抗体水平与术后第15、30天比较无统计学差异;但是与术后第90、180天比较有统计学差异(P<0.01)。结论:鼻息肉和EBV感染有关,鼻息肉患者血清抗EBV-LMP1抗体水平随着疾病的有效治疗而下降,可作为评价临床疗效的有效指标。

Objective：To detect the serum Epstain-Barr virus（EBV）latent membrane protein 1（LMP1）antibody and to appraise its clinical significance in patients with nasal polyps.Methods：There were 20 patients with nasal polyps who were managed by functional endoscopic sinus surgery（FESS） in experimental group,20 cases of healthy volunteers in control group.The anti-LMP1 antibody in sera of two groups before operation and 15,30,90,180 days after operation were detected by ELISA and Western blot using glutathione-EBV-LMP1 extracellular domain fusion protein（GST-LMP1）as the antigen.Results：The average levels of serum anti-EBV-LMP1 antibody displayed by absorbance of ELISA in nasal polyps group and control group were significantly different（0.976±0.131 vs.0.400±0.102,P 0.01）.The levels of anti-EBV-LMP1 antibody in the patients with nasal polyps before operation and 15,30,90 and 180 days after surgery were 0.976±0.131,0.921±0.138,0.899±0.168,0.576±0.144 and 0.521±0.117,respectively.The anti-EBV-LMP1 levels in sera of patients with nasal polyp decreased significantly in postoperative day 90 and 180 compared with those before operation（P 0.01）,but there was no significant difference among the levels before operation and in postoperative day 15 and 30.Western blot also showed the same changes.Conclusion：Nasal polyp may be closely related to EBV infection,the serum anti-LMP1 antibody level in the patients with nasal polyp declined following effective treatment,and it may be used as a valid indicator of clinical therapeutic efficacy.